Evidence map›Paper›PMID 33471628›Full record

ReviewAmerican journal of physiology. Gastrointestinal and liver physiology2021

Understanding chemotherapy-induced intestinal mucositis and strategies to improve gut resilience.

Alexander T Sougiannis, Brandon N VanderVeen, J Mark Davis, Daping Fan, E Angela Murphy

Open access · greenAbstract readReview
In one paragraph

Review in American journal of physiology. Gastrointestinal and liver physiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 1 pooled it
13.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 1 synthesis or guideline pooled it, 147 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Biomolecules · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. The Brown Strain ofInternational journal of molecular sciences · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Alexander T SougiannisDepartment of Pathology, Microbiology and Immunology, School of Medicine, University of South Carolina, South Carolina.
Brandon N VanderVeenDepartment of Pathology, Microbiology and Immunology, School of Medicine, University of South Carolina, South Carolina.
J Mark DavisAcePre, LLC, Columbia, South Carolina.
Daping FanAcePre, LLC, Columbia, South Carolina.
E Angela MurphyDepartment of Pathology, Microbiology and Immunology, School of Medicine, University of South Carolina, South Carolina.
University of South Carolina · USMedical University of South Carolina · US

Funding

Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracilR41AT009964 · NCCIH · ACEPRE, LLC · PI MURPHY, ELIZABETH ANGELA · 2018 to 2019
$300k
Enhancing the efficacy of 5 fluorouracil using emodin as a complementary therapeuticF31AT009820 · NCCIH · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI SOUGIANNIS, ALEXANDER THEODORE · 2018 to 2020
$98k
NCCIH NIH HHS F31 AT009820NCCIH NIH HHS R41 AT009964
6 · The paper itself

Abstract

Intestinal mucositis remains one of the most debilitating side effects related to chemotherapy. The onset and persistence of mucositis is an intricate physiological process involving cross-communication between the specific chemotherapeutic drug, the immune system, and gut microbes that results in a loss of mucosal integrity leading to gut-barrier dysfunction. Intestinal mucositis has a severe impact on a patient's quality of life and negatively influences the outcome of treatment. Most importantly, intestinal mucositis is a major contributor to the decreased survival rates and early onset of death associated with certain chemotherapy treatments. Understanding the pathophysiology and symptomology of intestinal mucositis is important in reducing the negative consequences of this condition. Prophylaxis, early diagnosis, and proper symptom management are essential to improved survival outcomes in patients with cancer. This review focuses on the pathobiology of intestinal mucositis that accompanies chemotherapy treatments. In addition, we will discuss the therapeutic potential of select strategies that have shown promise in mitigating chemotherapies' off-target effects without hampering their anticancer efficacy.

Indexed as

Antineoplastic AgentsHumansIntestinal MucosaMucositisAntineoplastic Agentschemotherapygut resilienceinflammationintestinal mucositistherapeutic strategies

Identifiers

PMID33471628
PMCPMC8202195
OpenAlexW3125726074

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.